Pipeline

Product Candidate Indication IND Phase 1 Phase 2 Phase 3 NDA Approved
Approved
In Progress
Planned
Abstral® (fentanyl) Sublingual Tablets Breakthrough Cancer Pain (BTcP)
NeuVax™ (nelipepimut-S) Breast Cancer Node Positive, HER2 IHC 1+/2+
NeuVax™ + Herceptin® (trastuzumab) Breast Cancer Node Positive & Negative, HER2 IHC 1+/2+
NeuVax™ + Herceptin® (trastuzumab) Breast Cancer Neoadjuvant, Node Positive & Negative, HER2 IHC 3+
NeuVax™ (nelipepimut-S) Gastric Cancer HER2 IHC 1+/2+ or 3+
GALE-301 (Folate Binding Protein(FBP)) Ovarian & Endometrial Cancers
GALE-401 (Anagrelide CR) Essential Thrombocythemia (ET)

*NeuVax is an investigational product.  Efficacy has not been established.